loading
전일 마감가:
$3.06
열려 있는:
$3.25
하루 거래량:
22,067
Relative Volume:
0.31
시가총액:
$28.24M
수익:
-
순이익/손실:
$-45.57M
주가수익비율:
-4.873
EPS:
-0.63
순현금흐름:
$-38.56M
1주 성능:
-20.00%
1개월 성능:
-2.95%
6개월 성능:
+1.72%
1년 성능:
-66.44%
1일 변동 폭
Value
$2.95
$3.25
1주일 범위
Value
$2.95
$3.6975
52주 변동 폭
Value
$2.16
$69.99

Sab Biotherapeutics Inc Stock (SABS) Company Profile

Name
명칭
Sab Biotherapeutics Inc
Name
전화
305-845-2813
Name
주소
777 W 41ST ST, MIAMI BEACH
Name
직원
57
Name
트위터
Name
다음 수익 날짜
2024-11-12
Name
최신 SEC 제출 서류
Name
SABS's Discussions on Twitter

SABS을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
SABS 3.06 28.24M 0 -45.57M -38.56M -0.63
VRTX 448.94 115.43B 10.63B -479.80M -1.35B 13.33
REGN 746.62 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 597.27 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 246.44 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 108.05 24.89B 3.30B -501.07M 1.03B 11.54

Sab Biotherapeutics Inc Stock (SABS) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2021-11-05 개시 Chardan Capital Markets Buy

Sab Biotherapeutics Inc 주식(SABS)의 최신 뉴스

pulisher
Nov 11, 2024

SABS FY2024 EPS Reduced by Brookline Capital Management - Defense World

Nov 11, 2024
pulisher
Nov 09, 2024

SAB Biotherapeutics Third Quarter 2024 Earnings: US$1.12 loss per share (vs US$0.97 loss in 3Q 2023) - Yahoo Finance

Nov 09, 2024
pulisher
Nov 06, 2024

SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update - GlobeNewswire

Nov 06, 2024
pulisher
Nov 06, 2024

SAB Bio's Q3 Loss Widens to $10.3M Despite Progress in Diabetes Drug Trial | SABS Stock News - StockTitan

Nov 06, 2024
pulisher
Oct 31, 2024

SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference - GlobeNewswire

Oct 31, 2024
pulisher
Oct 21, 2024

Critical Comparison: Sana Biotechnology (NASDAQ:SANA) & SAB Biotherapeutics (NASDAQ:SABS) - Defense World

Oct 21, 2024
pulisher
Oct 17, 2024

SAB Biotherapeutics Inc (SABS) Getting Ready To Launch, Waiting For The Long Term Buyers - Stocks Register

Oct 17, 2024
pulisher
Oct 14, 2024

Influenza Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail

Oct 14, 2024
pulisher
Sep 28, 2024

Short Interest in SAB Biotherapeutics, Inc. (NASDAQ:SABS) Declines By 12.7% - Defense World

Sep 28, 2024
pulisher
Sep 24, 2024

Saba Capital Income & Opportunities Fund II (NYSE:SABA) Major Shareholder Sells $37,672.38 in Stock - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

Metric Analysis: Cassava Sciences Inc (SAVA)’s Key Ratios in the Limelight - The Dwinnex

Sep 24, 2024
pulisher
Sep 24, 2024

Healthy Upside Potential: Sabre Corp (SABR) - SETE News

Sep 24, 2024
pulisher
Sep 24, 2024

Assembly Biosciences keeps Neutral rating after Phase 1a study results - Investing.com

Sep 24, 2024
pulisher
Sep 24, 2024

DSMB endorses continuation of Alzheimer's drug trials - Investing.com India

Sep 24, 2024
pulisher
Sep 23, 2024

Cassava Sciences Unusual Options Activity For September 23 - Benzinga

Sep 23, 2024
pulisher
Sep 23, 2024

SAB Biotherapeutics (NASDAQ:SABS) Will Have To Spend Its Cash Wisely - Yahoo Finance

Sep 23, 2024
pulisher
Sep 22, 2024

Renaissance Technologies LLC Lowers Stock Position in SBA Communications Co. (NASDAQ:SBAC) - Defense World

Sep 22, 2024
pulisher
Sep 22, 2024

Sabre Corporation (SABR): Among the Worst AI Stocks To Buy Under $10 - Yahoo Finance

Sep 22, 2024
pulisher
Sep 20, 2024

Acumen Health Holdings ("Acumen") to Acquire the Avenova brand from NovaBay Pharmaceuticals - Morningstar

Sep 20, 2024
pulisher
Sep 14, 2024

SAB Biotherapeutics (NASDAQ:SABS) Stock Rating Reaffirmed by Oppenheimer - Defense World

Sep 14, 2024
pulisher
Sep 13, 2024

SAB Biotherapeutics, Inc. (NASDAQ:SABSW) Short Interest Update - Defense World

Sep 13, 2024
pulisher
Sep 13, 2024

SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference - GlobeNewswire

Sep 13, 2024
pulisher
Sep 10, 2024

SAB Biotherapeutics (NASDAQ:SABS) Given “Buy” Rating at Chardan Capital - Defense World

Sep 10, 2024
pulisher
Sep 09, 2024

SAB BIO Provides SAB-142 Clinical Trial Progress Update at - GlobeNewswire

Sep 09, 2024
pulisher
Sep 09, 2024

SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the - The Bakersfield Californian

Sep 09, 2024
pulisher
Sep 09, 2024

SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting - StockTitan

Sep 09, 2024
pulisher
Sep 04, 2024

SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting - GlobeNewswire

Sep 04, 2024
pulisher
Aug 28, 2024

SAB Biotherapeutics (NASDAQ:SABS) Coverage Initiated by Analysts at Oppenheimer - Defense World

Aug 28, 2024
pulisher
Aug 27, 2024

How To Buy SAB Biotherapeutics, Inc. Stock Online in August 2024 - Traders Union

Aug 27, 2024
pulisher
Aug 26, 2024

Influenza Pipeline Drugs 2024 | Moderna, SAB Biotherapeutics, ENA Respiratory Pty Ltd, Codagenix, AlloVir, Osivax, CureVac AG - Barchart

Aug 26, 2024
pulisher
Aug 26, 2024

Influenza Pipeline Drugs 2024 | Moderna, SAB Biotherapeutics, - openPR

Aug 26, 2024
pulisher
Aug 15, 2024

Chardan Capital Analysts Boost Earnings Estimates for SAB Biotherapeutics, Inc. (NASDAQ:SABS) - Defense World

Aug 15, 2024
pulisher
Aug 12, 2024

SAB Biotherapeutics (NASDAQ:SABS) Receives Buy Rating from HC Wainwright - Defense World

Aug 12, 2024
pulisher
Aug 12, 2024

SAB Biotherapeutics (NASDAQ:SABS) Stock Rating Reaffirmed by Chardan Capital - Defense World

Aug 12, 2024
pulisher
Aug 09, 2024

SABS stock touches 52-week low at $2.3 amid market challenges - Investing.com

Aug 09, 2024
pulisher
Aug 08, 2024

SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates - GlobeNewswire

Aug 08, 2024
pulisher
Aug 08, 2024

Seasonal Influenza Treatment Market Size 2032 | SAb - openPR

Aug 08, 2024
pulisher
Aug 05, 2024

SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes - GlobeNewswire

Aug 05, 2024
pulisher
Jul 31, 2024

SAB BIO Appoints Lucy To as Chief Financial Officer - citybiz

Jul 31, 2024
pulisher
Jul 21, 2024

SAB Biotherapeutics (NASDAQ:SABS) Trading Down 0.4% - American Banking and Market News

Jul 21, 2024
pulisher
Jul 01, 2024

MarketBeat June market recap - SiouxFalls.Business

Jul 01, 2024
pulisher
Jun 30, 2024

SAB Biotherapeutics to Present at the Ladenburg Thalmann Annual Healthcare Conference 2021 - Quantisnow

Jun 30, 2024
pulisher
Jun 30, 2024

Big Cypress Acquisition Corp. Reports Ladenburg Conference Presentation by Planned Merger Partner SAB Biotherapeutics - Quantisnow

Jun 30, 2024
pulisher
Jun 30, 2024

SAB Biotherapeutics Announces Publication of Preclinical Data Demonstrating SAB-185 Effectively Neutralizes SARS ... - Quantisnow

Jun 30, 2024
pulisher
Jun 30, 2024

SAB Biotherapeutics Announces Nonclinical Data Demonstrating SAB-185 Potently Neutralizes Delta and Lambda ... - Quantisnow

Jun 30, 2024
pulisher
Jun 30, 2024

SAB Biotherapeutics to List on Nasdaq through Merger with Big Cypress Acquisition Corp., Advancing Unique Human ... - Quantisnow

Jun 30, 2024
pulisher
Jun 28, 2024

Reviewing SAB Biotherapeutics (NASDAQ:SABS) & Quantum Genomics Société Anonyme (OTCMKTS:QNNTF) - Defense World

Jun 28, 2024
pulisher
Jun 27, 2024

Cathie Wood's ARK ETF focuses on PagerDuty, 10X Genomics stock By Investing.com - Investing.com

Jun 27, 2024
pulisher
Jun 27, 2024

Tenaya Therapeutics Announces Director Resignation By Investing.com - Investing.com

Jun 27, 2024
pulisher
Jun 27, 2024

CSP Inc insider buys shares worth over $23,000 - Investing.com

Jun 27, 2024
pulisher
Jun 27, 2024

Kintara Therapeutics restructures share designations By Investing.com - Investing.com

Jun 27, 2024

Sab Biotherapeutics Inc (SABS) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Sab Biotherapeutics Inc 주식 (SABS) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
King Michael
CHIEF FINANCIAL OFFICER
Nov 30 '23
Buy
0.90
5,000
4,500
5,000
Reich Samuel J
Executive Chairman
Nov 29 '23
Buy
0.89
11,000
9,842
219,001
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
자본화:     |  볼륨(24시간):